Search clinical trials for: Inhaled Insulin

Total 3793 results

Novo Nordisk A/S

Completed

Frequency of Hypoglycaemic Episodes During Treatment With Insulin Detemir in Well Controlled Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Denmark, Croatia, Australia, South Africa, Italy, Sweden
Novo Nordisk A/S

Completed

A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily (BOOST®)

Diabetes Mellitus, Type 2 | Diabetes

United States, Malaysia, Germany, Algeria, Turkey
Rigshospitalet, Denmark

Completed

Effects of Insulin Detemir and NPH Insulin on Renal Handling of Sodium, Fluid Retention, and Weight in Type 2 Diabetic Patients (Le-Na)

Weight Gain | Diabetes Type 2

Denmark
Novo Nordisk A/S

Completed

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes (onset®8)

Diabetes | Diabetes Mellitus, Type 1

United States, India, Israel, Italy, Japan, Russian Federation, Canada, Austria, Taiwan, Serbia, Germany, Bulgaria, Puerto Rico
Novo Nordisk A/S

Completed

Efficacy and Safety of Insulin Aspart in Subjects With Type 1 or Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

China
Sanofi

Completed

Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents

Diabetes Mellitus, Insulin-Dependent

United States
Novo Nordisk A/S

Completed

Safety, Pharmacokinetics and Pharmacodynamics of Two IDegAsp (One Explorative) Preparations and Two Insulin Degludec (One Explorative) Preparations in Japanese Subjects

Healthy | Diabetes

Japan
Northwestern University

Completed

Study of Glycemic Control on Liver Transplantation Outcomes

Hyperglycemia | Rejection | Evidence of Liver Transplantation

United States
Novo Nordisk A/S

Completed

Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes (onset® 1)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, Finland, Belgium, Hungary, United Kingdom, Germany, Canada, Czechia
Novo Nordisk A/S

Completed

Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Israel, Poland, United Kingdom, Denmark, Spain, France, Austria, Norway, Russian Federation, Canada, Croatia, Argentina, South Africa, Australia, Ireland, Brazil, Finland
Amsterdam UMC, location VUmc

Completed

Insulin Detemir Action in Cerebro (INcEREBRO)

Type 1 Diabetes

Netherlands
Novo Nordisk A/S

Terminated

Comparison of Insulin Detemir and NPH Insulin Given Once Daily in Ageing Subjects With Type 2 Diabetes (3L)

Diabetes Mellitus, Type 2 | Diabetes

United Kingdom, France
Novo Nordisk A/S

Completed

Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany, Austria, South Africa
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir and NPH With Respect to Lowering the Blood Sugar and Symptoms Experienced by Type 1 Diabetics During Hypoglycaemia

Diabetes | Diabetes Mellitus, Type 1

United Kingdom
Novo Nordisk A/S

Completed

Efficacy and Safety of Insulin Detemir in Type 2 Diabetes Inadequately Controlled on OHA Therapy Alone

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Sweden, Finland, France, Norway
Novo Nordisk A/S

Completed

Observational Study of Patients Using Levemir® or Insulatard® as Start Insulin for Treatment of Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Slovenia
Novo Nordisk A/S

Completed

Comparison of Two NN5401 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany, Spain, France, Norway, Romania
Novo Nordisk A/S

Completed

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes (onset®7)

Diabetes | Diabetes Mellitus, Type 1

Germany, United States, India, Israel, Italy, Russian Federation, Japan, Finland, Serbia, Turkey, Bulgaria, Estonia, Czechia, Lithuania, Ukraine, Poland, Latvia, Puerto Rico
Lise Tarnow
Novo Nordisk A/S

Completed

Insulin Analogues and Severe Hypoglycaemia

Type 1 Diabetes

Denmark
National Heart, Lung, and Blood Institute (NHLBI)
Childhood Asthma Research and Education Network

Completed

Pediatric Asthma Controller Trial (PACT)

Lung Diseases | Asthma
Arkansas Children's Hospital Research Institute

Completed

In-Vivo Evaluation of Nebulized Aerosols Delivered Via Nasal Route

Interface Acceptance During Delivery of Aerosol Medicine to an Infant or Child

United States
University of Florida
Novo Nordisk A/S; VA Office of Research and Development

Completed

Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes

Type 2 Diabetes

United States
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Italy, Russian Federation, Slovakia, Spain, Ireland, Germany, Turkey, Bulgaria, Hong Kong, Romania, South Africa
Novo Nordisk A/S

Completed

Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Safety and Efficacy of Insulin Detemir in Combination With OAD in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Poland, Russian Federation, Denmark, Sweden, Macedonia, The Former Yugoslav Republic of, Norway, Croatia, France, Belgium, Slovakia
Novo Nordisk A/S

Completed

Comparing Insulin Aspart With Fast-acting Insulin Human in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir and Insulin Aspart in 2 Separate Injections Twice Daily to Extemporaneous Mixing Injection Regimen Twice Daily - The Paediatric Mixing Trial (MIXING)

Diabetes | Diabetes Mellitus, Type 1

France
Novo Nordisk A/S

Completed

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United States, Sweden, Norway, Germany, Australia
Novo Nordisk A/S

Completed

Self-control Trial to Evaluate the Remission Rate in Newly Diagnosed Type 2 Diabetes Patients After Treatment With Insulin Aspart

Diabetes Mellitus, Type 2 | Diabetes

China
University of Giessen
Sanofi

Completed

Comparison of Insulin Glargine and NPH Insulin at Night and at Hypoglycemia in Type 2 Diabetes (ClampHOE901)

Diabetes

Germany
Heidelberg University
Bayer

Withdrawn

Iloprost for Bridging to Heart Transplantation in PH (BRIDGE)

Pulmonary Hypertension | Chronic Left Ventricular Failure

Germany
University of Oxford
University of Birmingham

Terminated

MVA85A Aerosol vs Intramuscular Vaccination in Adults With Latent Mycobacterium Tuberculosis (M. tb) Infection

Tuberculosis

United Kingdom
Novo Nordisk A/S

Completed

Comparison of Antibody Levels in Children and Adolescents After Initiation of Insulin Therapy by Either Insulin Aspart or Soluble Human Insulin

Diabetes | Diabetes Mellitus, Type 1

Sweden
Novo Nordisk A/S

Completed

Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, United Kingdom, Denmark, Netherlands, Norway, South Africa, Finland, France, Spain, Former Serbia and Montenegro, Sweden
Novo Nordisk A/S

Completed

Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen (Full STEP™)

Diabetes Mellitus, Type 2 | Diabetes

United States, France, Argentina, Macedonia, The Former Yugoslav Republic of, Slovenia, Canada, Brazil
Sanofi

Completed

Efficacy Study on the Control of Blood Glucose Concentration in Type 1 Diabetic Patients (VARIABILITE)

Diabetes Mellitus, Type 1

France
Novo Nordisk A/S

Completed

Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes (Onset® 5)

Diabetes | Diabetes Mellitus, Type 1

United States, Russian Federation, United Kingdom, Canada, France, Netherlands, Belgium, Germany, Slovenia
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Observational Study of Type 2 Diabetes Patients Failing on Oral Anti-diabetic Agents Initiated on Levemir® or Insulatard® (EVIDENCE)

Diabetes Mellitus, Type 2 | Diabetes

Romania
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Sanofi

Completed

Effect of Insulin Glargine in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s)

Diabetes Mellitus, Type 2

United States, Canada
Novo Nordisk A/S

Completed

Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, France, Sweden, Poland, Turkey, Korea, Republic of, India, South Africa
Novo Nordisk A/S

Completed

Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes (BEGIN™)

Diabetes | Diabetes Mellitus, Type 1

India, Italy, United Kingdom, Finland, Japan, Argentina, Macedonia, The Former Yugoslav Republic of, Brazil
Novo Nordisk A/S

Completed

Comparison of NN1250 Versus Insulin Detemir, Both Combined With Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United States, United Kingdom, France, Netherlands, Finland, Germany, Sweden
Novo Nordisk A/S

Completed

Pharmacokinetics of Insulin Detemir in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus (BEGIN™)

Diabetes | Diabetes Mellitus, Type 1

Germany, France, United States, Japan, Netherlands, Russian Federation, Bulgaria, United Kingdom, North Macedonia, South Africa, Italy, Finland
Novo Nordisk A/S

Completed

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes (SWITCH 1)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, Puerto Rico

3

Subscribe